特发性肺纤维化抗体药物研发进展  

Research and development progress of antibody drugs for idiopathic pulmonary fibrosis

作　　者：苗洋 李霄鹤 翟芸芊 白佳坤 马晓阳 希布日 张建伟 周红刚 杨诚 MIAO Yang;LI Xiao-he;ZHAI Yun-qian;BAI Jia-kun;MA Xiao-yang;XI Bu-riZHANG Jian-wei;ZHOU Hong-gang;YANG Cheng(State Key Lab of Medicinal Chemical Biology,Tianjin Key Lab of Molecular Drug Research,College of Pharmacy,Nankai University,Tianjin 300350,China)

机构地区：[1]南开大学药学院,药物化学生物学国家重点实验室,天津市分子药物研究重点实验室,天津300350

出　　处：《药学学报》2021年第11期2881-2886,共6页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(82070060)。

摘　　要：特发性肺纤维化是一种纤维化疾病。目前其发病机制尚未被完全阐明,而且没有确切治疗效果的药物用于此疾病。抗体药物经过4个阶段的发展,以其自身优势正成为药物研发的新热点。目前,已有多款药物进入临床试验研究阶段。基于此,本文总结了针对特发性肺纤维化临床试验研究阶段的抗体药物,以期对抗体药物的发展进行总结,为抗体药物的研发提供一定的依据与思路。Idiopathic pulmonary fibrosis is a fibrous disease. At present, its pathogenesis has not been fully elucidated and there is no drug with definite therapeutic effect. After four stages of development, antibody drugs are becoming a new hotspot in drug research and development with their own advantages. A number of drugs have entered the stage of clinical trials. Based on this, this review summarizes the antibody drugs for the clinical stage of clinical research of idiopathic pulmonary fibrosis, in order to summarize the development of antibody drugs, and provide certain bases and ideas for the development of antibody drugs.

关 键 词：特发性肺纤维化 发病机制 抗体药物 靶点 临床试验 

分 类 号：R967[医药卫生—药理学]